论文部分内容阅读
目的:探讨莫西沙星联合哌拉西林钠他唑巴坦钠治疗重症肺炎的临床疗效。方法:选择本院2013年1月至2015年1月收治的重症肺炎患者100例,按照随机原则将全部患者分成对照组和观察组,各50例,全部患者均给予临床常规对症治疗,对照组患者在常规对症治疗的同时采用左氧氟沙星联合哌拉西林钠他唑巴坦钠治疗,观察组患者则在常规对症治疗的同时采用莫西沙星联合哌拉西林钠他唑巴坦钠治疗。结果:观察组患者的临床治疗总有效率显著高于对照组患者(P<0.05);观察组患者的机械通气时间、临床症状改善时间均显著短于对照组患者(P<0.05);治疗后观察组患者的氧分压(Pa O2)、天冬氨酸氨基转移酶(AST)、谷丙转氨酶(ALT)水平显著高于对照组(P<0.05),白细胞计数(WBC)水平显著低于对照组患者(P<0.05)。结论:在对重症肺炎患者进行治疗时,莫西沙星联合哌拉西林钠他唑巴坦钠治疗具有比较显著的临床治疗效果,能对患者的临床症状进行有效改善,缩短治疗时间,促进患者更快康复。
Objective: To investigate the clinical efficacy of moxifloxacin in combination with piperacillin and tazobactam in the treatment of severe pneumonia. Methods: 100 cases of severe pneumonia admitted from January 2013 to January 2015 in our hospital were selected. All patients were divided into control group and observation group according to the randomized principle. All patients were given conventional symptomatic treatment and control group Patients in the conventional symptomatic treatment with levofloxacin combined with piperacillin sodium tazobactam sodium treatment, the observation group were in the conventional symptomatic treatment with moxifloxacin combined with piperacillin sodium tazobactam sodium. Results: The total effective rate of clinical treatment in observation group was significantly higher than that in control group (P <0.05). The duration of mechanical ventilation and the improvement of clinical symptoms in observation group were significantly shorter than those in control group (P <0.05) PaO2, AST and ALT in the observation group were significantly higher than those in the control group (P <0.05), and the WBC levels were significantly lower than those in the control group Control group patients (P <0.05). Conclusion: Moxifloxacin combined with piperacillin and tazobactam sodium has significant effect in clinical treatment of patients with severe pneumonia, which can effectively improve the clinical symptoms of patients, shorten the treatment time and promote more patients Quick recovery.